# Moleculin Biotech, Inc. (MBRX) — capital_raise/atm_program [pending]
Source: SEC API (secapi.ai) · situation sit_7f673eb699e489aa06be · retrieved 2026-08-11T15:49:14.826Z

## Overview
Moleculin Biotech, Inc. is a pharmaceutical company developing Annamycin, a cancer therapeutic candidate.

Moleculin Biotech, Inc. completed a public offering on August 3, 2026, selling 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof) and Series I Common Stock Purchase Warrants to purchase up to 37,130,001 shares of common stock at a combined public offering price of $0.75 per share and accompanying warrant. The offering generated gross proceeds of approximately $9.3 million before deducting placement agent fees and other offering expenses. Roth Capital Partners, LLC served as the placement agent and received a cash fee of 6.5% of gross proceeds plus reimbursement of up to $100,000 in out-of-pocket expenses. The company intends to use the net proceeds to advance Annamycin through clinical development and for working capital.

## Terms
- Counterparty: Roth Capital Partners, LLC · Deal value: $9.3M · Consideration: mixed · Price/share: $0.75

## Key dates
- Announced 2026-08-03

## Timeline
- 2026-08-03 · 8-K (0001437749-26-025474): 8-K - Moleculin Biotech, Inc. — *Moleculin Biotech, Inc. is a pharmaceutical company developing Annamycin, a cancer therapeutic candidate.* Moleculin Biotech, Inc. completed a public offering on August 3, 2026, selling 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof) and Series I Common Stock Purchase Warrants to purchase up to 37,130,001 shares of common stock at a combined public offering price of $0.75 per share and accompanying warrant. The offering generated gross proceeds of approximately $9.3 million before deducting placement agent fees and other offering expenses. Roth Capital Partners, LLC served as the placement agent and received a cash fee of 6.5% of gross proceeds plus reimbursement of up to $100,000 in out-of-pocket expenses. The company intends to use the net proceeds to advance Annamycin through clinical development and for working capital.
  https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-025474.txt

## Citations
- 0001437749-26-025474 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000143774926025474